Trials / Completed
CompletedNCT02539966
Safety & Performance Study of the FANTOM Sirolimus-Eluting Bioresorbable Coronary Scaffold
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 272 (actual)
- Sponsor
- REVA Medical, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The FANTOM II trial is intended to assess safety and performance of the Fantom Bioresorbable Coronary Scaffold in native coronary arteries.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Fantom Sirolimus-Eluting Coronary Bioresorbable Scaffold | Bioresorbable Drug-Eluting Scaffold Implantation for the Treatment of Coronary Artery Disease |
Timeline
- Start date
- 2015-03-01
- Primary completion
- 2019-08-01
- Completion
- 2024-09-01
- First posted
- 2015-09-03
- Last updated
- 2025-04-04
Locations
28 sites across 8 countries: Australia, Belgium, Brazil, Denmark, France, Germany, Netherlands, Poland
Source: ClinicalTrials.gov record NCT02539966. Inclusion in this directory is not an endorsement.